Search Results - "Sweha, Stefan R"

Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas by Chung, Chan, Sweha, Stefan R., Pratt, Drew, Tamrazi, Benita, Panwalkar, Pooja, Banda, Adam, Bayliss, Jill, Hawes, Debra, Yang, Fusheng, Lee, Ho-Joon, Shan, Mengrou, Cieslik, Marcin, Qin, Tingting, Werner, Christian K., Wahl, Daniel R., Lyssiotis, Costas A., Bian, Zhiguo, Shotwell, J. Brad, Yadav, Viveka Nand, Koschmann, Carl, Chinnaiyan, Arul M., Blüml, Stefan, Judkins, Alexander R., Venneti, Sriram

“…H3K27M diffuse intrinsic pontine gliomas (DIPGs) are fatal and lack treatments. They mainly harbor H3.3K27M mutations resulting in H3K27me3 reduction…”
Get full text

Targeting SWI/SNF ATPases in H3.3K27M diffuse intrinsic pontine gliomas by Mota, Mateus, Sweha, Stefan R, Pun, Matt, Natarajan, Siva Kumar, Ding, Yujie, Chung, Chan, Hawes, Debra, Yang, Fusheng, Judkins, Alexander R, Samajdar, Susanta, Cao, Xuhong, Xiao, Lanbo, Parolia, Abhijit, Chinnaiyan, Arul M, Venneti, Sriram

“…Diffuse midline gliomas (DMGs) including diffuse intrinsic pontine gliomas (DIPGs) bearing lysine-to-methionine mutations in histone H3 at lysine 27 (H3K27M)…”
Get full text

Therapeutic targeting of differentiation-state dependent metabolic vulnerabilities in diffuse midline glioma by Mbah, Nneka E., Myers, Amy L., Sajjakulnukit, Peter, Chung, Chan, Thompson, Joyce K., Hong, Hanna S., Giza, Heather, Dang, Derek, Nwosu, Zeribe C., Shan, Mengrou, Sweha, Stefan R., Maydan, Daniella D., Chen, Brandon, Zhang, Li, Magnuson, Brian, Zhu, Zirui, Radyk, Megan, Lavoie, Brooke, Yadav, Viveka Nand, Koo, Imhoi, Patterson, Andrew D., Wahl, Daniel R., Franchi, Luigi, Agnihotri, Sameer, Koschmann, Carl J., Venneti, Sriram, Lyssiotis, Costas A.

“…H3K27M diffuse midline gliomas (DMG), including diffuse intrinsic pontine gliomas (DIPG), exhibit cellular heterogeneity comprising less-differentiated…”
Get full text

Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas by Sweha, Stefan R, Chung, Chan, Natarajan, Siva Kumar, Panwalkar, Pooja, Pun, Matthew, Ghali, Amer, Bayliss, Jill, Pratt, Drew, Shankar, Anand, Ravikumar, Visweswaran, Rao, Arvind, Cieslik, Marcin, Wilder-Romans, Kari, Scott, Andrew J, Wahl, Daniel R, Jessa, Selin, Kleinman, Claudia L, Jabado, Nada, Mackay, Alan, Jones, Chris, Martinez, Daniel, Santi, Mariarita, Judkins, Alexander R, Yadav, Viveka Nand, Qin, Tingting, Phoenix, Timothy N, Koschmann, Carl J, Baker, Suzanne J, Chinnaiyan, Arul M, Venneti, Sriram

“…High-grade gliomas with arginine or valine substitutions of the histone H3.3 glycine-34 residue (H3.3G34R/V) carry a dismal prognosis, and current treatments,…”
Get more information

Molecular biomarkers predictive of sertraline treatment response in young children with fragile X syndrome by AlOlaby, Reem Rafik, Sweha, Stefan R, Silva, Marisol, Durbin-Johnson, Blythe, Yrigollen, Carolyn M, Pretto, Dalyir, Hagerman, Randi J, Tassone, Flora

“…Abstract Objectives Several neurotransmitters involved in brain development are altered in fragile X syndrome (FXS), the most common monogenic cause of autism…”
Get full text

Clinical and molecular correlates in fragile X premutation females by Jiraanont, Poonnada, Sweha, Stefan R., AlOlaby, Reem R., Silva, Marisol, Tang, Hiu-Tung, Durbin-Johnson, Blythe, Schneider, Andrea, Espinal, Glenda M., Hagerman, Paul J., Rivera, Susan M., Hessl, David, Hagerman, Randi J., Chutabhakdikul, Nuanchan, Tassone, Flora

“…The prevalence of the fragile X premutation (55–200 CGG repeats) among the general population is relatively high, but there remains a lack of clear…”
Get full text

Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma by Messinger, Dana, Harris, Micah K, Cummings, Jessica R, Thomas, Chase, Yang, Tao, Sweha, Stefan R, Woo, Rinette, Siddaway, Robert, Burkert, Martin, Stallard, Stefanie, Qin, Tingting, Mullan, Brendan, Siada, Ruby, Ravindran, Ramya, Niculcea, Michael, Dowling, Abigail R, Bradin, Joshua, Ginn, Kevin F, Gener, Melissa A H, Dorris, Kathleen, Vitanza, Nicholas A, Schmidt, Susanne V, Spitzer, Jasper, Li, Jiang, Filbin, Mariella G, Cao, Xuhong, Castro, Maria G, Lowenstein, Pedro R, Mody, Rajen, Chinnaiyan, Arul, Desprez, Pierre-Yves, McAllister, Sean, Dun, Matthew D, Hawkins, Cynthia, Waszak, Sebastian M, Venneti, Sriram, Koschmann, Carl, Yadav, Viveka Nand

“…Diffuse midline gliomas (DMG) are highly invasive brain tumors with rare survival beyond two years past diagnosis and limited understanding of the mechanism…”
Get full text

Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways by Venneti, Sriram, Kawakibi, Abed Rahman, Ji, Sunjong, Waszak, Sebastian M, Sweha, Stefan R, Mota, Mateus, Pun, Matthew, Deogharkar, Akash, Chung, Chan, Tarapore, Rohinton S, Ramage, Samuel, Chi, Andrew, Wen, Patrick Y, Arrillaga-Romany, Isabel, Batchelor, Tracy T, Butowski, Nicholas A, Sumrall, Ashley, Shonka, Nicole, Harrison, Rebecca A, de Groot, John, Mehta, Minesh, Hall, Matthew D, Daghistani, Doured, Cloughesy, Timothy F, Ellingson, Benjamin M, Beccaria, Kevin, Varlet, Pascale, Kim, Michelle M, Umemura, Yoshie, Garton, Hugh, Franson, Andrea, Schwartz, Jonathan, Jain, Rajan, Kachman, Maureen, Baum, Heidi, Burant, Charles F, Mottl, Sophie L, Cartaxo, Rodrigo T, John, Vishal, Messinger, Dana, Qin, Tingting, Peterson, Erik, Sajjakulnukit, Peter, Ravi, Karthik, Waugh, Alyssa, Walling, Dustin, Ding, Yujie, Xia, Ziyun, Schwendeman, Anna, Hawes, Debra, Yang, Fusheng, Judkins, Alexander R, Wahl, Daniel, Lyssiotis, Costas A, de la Nava, Daniel, Alonso, Marta M, Eze, Augustine, Spitzer, Jasper, Schmidt, Susanne V, Duchatel, Ryan J, Dun, Matthew D, Cain, Jason E, Jiang, Li, Stopka, Sylwia A, Baquer, Gerard, Regan, Michael S, Filbin, Mariella G, Agar, Nathalie Y R, Zhao, Lili, Kumar-Sinha, Chandan, Mody, Rajen, Chinnaiyan, Arul, Kurokawa, Ryo, Pratt, Drew, Yadav, Viveka N, Grill, Jacques, Kline, Cassie, Mueller, Sabine, Resnick, Adam, Nazarian, Javad, Allen, Joshua E, Odia, Yazmin, Gardner, Sharon L, Koschmann, Carl

“…Patients with H3K27M-mutant diffuse midline glioma (DMG) have no proven effective therapies. ONC201 has recently demonstrated efficacy in these patients, but…”
Get more information